A propensity score-matched analysis of breast-conserving surgery plus whole-breast irradiation versus mastectomy in breast cancer.
Breast cancer
Breast conserving surgery
HER2
Mastectomy
Outcome
Radiotherapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
10
02
2022
accepted:
22
02
2022
pubmed:
8
3
2022
medline:
8
3
2023
entrez:
7
3
2022
Statut:
ppublish
Résumé
Recent observations regarding long-term outcomes among patients with early-stage breast cancer (BC) who underwent breast-conserving surgery (BCS) plus whole-breast irradiation (WBI) or mastectomy are from a small number of registry-based studies. Therefore, these findings may overestimate differences in survival between the two groups, compared with randomized controlled trials conducted in the 1980s. The aim of this study is to compare long-term outcomes and clinicopathologic characteristics between patients treated with BCS + WBI or mastectomy for BC. We performed a propensity score-matched analysis in a cohort of 9710 patients aged < 70 years who underwent BCS + WBI or mastectomy without external radiotherapy for a first primary BC (pT1-2, N0-3a) at the European Institute of Oncology between 2000 and 2008. Patients were matched by propensity score. Median follow-up was 8.4 years (interquartile range 6.5-10.2). The cumulative incidence of axillary lymph node recurrence at 10 years was lower in the BCS + WBI group [2.4% (95% CI, 1.7-3.3%)] than in the mastectomy group [4.4% (95% CI, 3.5-5.5%)] (P = .0005), and the cumulative incidence of contralateral BC was higher in the BCS + WBI group [3.9% (95% CI, 2.8-5.1%)] than in the mastectomy group [2.5% (95% CI, 1.7-3.4%)] (P = .01). Among the 366 patients with HER2 subtype BC, BCS + WBI was associated with a fivefold higher risk [hazard ratio 4.97 (95% CI, 2.28-10.8)] of ipsilateral breast tumor recurrence (IBTR), compared with mastectomy (P < .0001); however, among patients with other BC subtypes, the rates of IBTR were not statistically significantly different. Patients with HER2 subtype BC (T1-2, N0-3) who underwent BCS + WBI had a statistically significantly higher risk of IBTR than patients who underwent mastectomy. Survival was not statistically significantly different between the groups.
Identifiants
pubmed: 35254519
doi: 10.1007/s00432-022-03973-8
pii: 10.1007/s00432-022-03973-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1085-1093Subventions
Organisme : NCI NIH HHS
ID : Support Grant P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : Support Grant P30 CA008748
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abi Jaoude J, de Azambuja E, Makki M, Tamim H, Tfayli A, Geara F, Piccart M, Poortmans P, Zeidan YH (2020) Post-mastectomy radiation therapy in human epidermal growth factor receptor 2 positive breast cancer patients: analysis of the HERA trial. Int J Radiat Oncol Biol Phys 106(3):503–510. https://doi.org/10.1016/j.ijrobp.2019.10.022
doi: 10.1016/j.ijrobp.2019.10.022
pubmed: 31654782
Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J (2014) Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg 149(3):267–274. https://doi.org/10.1001/jamasurg.2013.3049
doi: 10.1001/jamasurg.2013.3049
pubmed: 24429935
Banelli B, Casciano I, Di Vinci A et al (2010) Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. Ann Oncol 21(6):1237–1242. https://doi.org/10.1093/annonc/mdp470
doi: 10.1093/annonc/mdp470
pubmed: 19875753
Begg CB, Ostrovnaya I, Geyer FC et al (2008) Contralateral breast cancers: independent cancers or metastases? Int J Cancer 142(2):347–356. https://doi.org/10.1002/ijc.31051
doi: 10.1002/ijc.31051
Billena C, Wilgucki M, Flynn J et al (2021) 10-year breast cancer outcomes in women ≤35 years of age. Int J Radiat Oncol Biol Phys 109(4):1007–1018. https://doi.org/10.1016/j.ijrobp.2020.10.022
doi: 10.1016/j.ijrobp.2020.10.022
pubmed: 33371964
Botteri E, Gentilini O, Rotmensz N et al (2012) Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution. Breast Cancer Res Treat 134(3):1221–1228. https://doi.org/10.1007/s10549-012-2044-2
doi: 10.1007/s10549-012-2044-2
pubmed: 22535015
Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK (2017) Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast 35:122–129. https://doi.org/10.1016/j.breast.2017.07.004
doi: 10.1016/j.breast.2017.07.004
pubmed: 28719811
Cady B (2007) Local therapy and survival in breast cancer. N Engl J Med 357(10):1051–1052
doi: 10.1056/NEJMc076272
pubmed: 17823994
Chen K, Liu J, Zhu L, Su F, Song E, Jacobs LK (2015) Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: a NCDB analysis. Oncotarget 6(37):40127–40140. https://doi.org/10.18632/oncotarget.5394
doi: 10.18632/oncotarget.5394
pubmed: 26517676
pmcid: 4741884
Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106. https://doi.org/10.1016/S0140-6736(05)67887-7
doi: 10.1016/S0140-6736(05)67887-7
pubmed: 16360786
Corso G, Maisonneuve P, Santomauro GI et al (2018) Ipsilateral breast tumor reappearance and contralateral breast cancer after primary breast cancer treatment: a comprehensive retrospective study of 15,168 patients. Oncology 95(3):147–155. https://doi.org/10.1159/000488764
doi: 10.1159/000488764
pubmed: 29847835
Corso G, Maisonneuve P, Massari G et al (2020) Validation of a novel nomogram for prediction of local relapse after surgery for invasive breast carcinoma. Ann Surg Oncol 27(6):1864–1874. https://doi.org/10.1245/s10434-019-08160-7
doi: 10.1245/s10434-019-08160-7
pubmed: 31965372
pmcid: 7523878
Darby S, McGale P, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. https://doi.org/10.1016/S0140-6736(11)61629-2
doi: 10.1016/S0140-6736(11)61629-2
pubmed: 22019144
von Elm E, Altman DG, Egger M et al (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 18(6):800–804. https://doi.org/10.1097/EDE.0b013e3181577654
doi: 10.1097/EDE.0b013e3181577654
Fisher B, Redmond C, Poisson R et al (1989) Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320(13):822–828. https://doi.org/10.1056/NEJM198903303201302
doi: 10.1056/NEJM198903303201302
pubmed: 2927449
Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241. https://doi.org/10.1056/NEJMoa022152
doi: 10.1056/NEJMoa022152
pubmed: 12393820
Fodor A, Brombin C, Mangili P et al (2021) Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized? Breast 55:45–54. https://doi.org/10.1016/j.breast.2020.12.004
doi: 10.1016/j.breast.2020.12.004
pubmed: 33326894
Gentilini OD, Cardoso MJ, Poortmans P (2017a) Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients. Breast 35:32–33. https://doi.org/10.1016/j.breast.2017.06.004
doi: 10.1016/j.breast.2017.06.004
pubmed: 28644995
Gentilini O, Botteri E, Leonardi MC et al (2017b) Ipsilateral axillary recurrence after breast conservative surgery: the protective effect of whole breast radiotherapy. Radiother Oncol 122(1):37–44. https://doi.org/10.1016/j.radonc.2016.12.021
doi: 10.1016/j.radonc.2016.12.021
pubmed: 28063695
Gillon P, Touati N, Breton-Callu C, Slaets L, Cameron D, Bonnefoi H (2017) Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994/BIG 1–00 study. Eur J Cancer 79:226–234. https://doi.org/10.1016/j.ejca.2017.04.012
doi: 10.1016/j.ejca.2017.04.012
pubmed: 28527420
Goldstein NS, Kestin L, Vicini F (2003) Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy. A clinicopathologic study of 607 neoplasms from 583 patients. Am J Clin Pathol 120(4):500–527. https://doi.org/10.1309/8941-VDAJ-MKY2-GCLX
doi: 10.1309/8941-VDAJ-MKY2-GCLX
pubmed: 14560562
Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist 12(1):20–37. https://doi.org/10.1634/theoncologist.12-1-20
doi: 10.1634/theoncologist.12-1-20
pubmed: 17227898
Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Nygård JF (2015) Survival is better after breast conserving therapy than mastectomy for early stage breast cancer: a registry-based follow-up study of Norwegian women primary operated between 1998 and 2008. Ann Surg Oncol 22(12):3836–3845. https://doi.org/10.1245/s10434-015-4441-3
doi: 10.1245/s10434-015-4441-3
pubmed: 25743325
pmcid: 4595537
Hooning MJ, Aleman BM, Hauptmann M et al (2008) Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 26(34):5561–5568. https://doi.org/10.1200/JCO.2007.16.0192
doi: 10.1200/JCO.2007.16.0192
pubmed: 18854572
Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA (2013) Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer 119(7):1402–1411. https://doi.org/10.1002/cncr.27795
doi: 10.1002/cncr.27795
pubmed: 23359049
Jansen LA, Backstein RM, Brown MH (2014) Breast size and breast cancer: a systematic review. J Plast Reconstr Aesthet Surg 67(12):1615–1623. https://doi.org/10.1016/j.bjps.2014.10.001
doi: 10.1016/j.bjps.2014.10.001
pubmed: 25456291
Kim H, Lee SB, Nam SJ et al (2021) Survival of breast-conserving surgery plus radiotherapy versus total mastectomy in early breast cancer. Ann Surg Oncol 28(9):5039–5047. https://doi.org/10.1245/s10434-021-09591-x
doi: 10.1245/s10434-021-09591-x
pubmed: 33492542
Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA (2015) Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 150(1):9–16. https://doi.org/10.1001/jamasurg.2014.2895
doi: 10.1001/jamasurg.2014.2895
pubmed: 25408966
Lagendijk M, van Maaren MC, Saadatmand S et al (2018) Breast conserving therapy and mastectomy revisited: breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. Int J Cancer 142(1):165–175. https://doi.org/10.1002/ijc.31034
doi: 10.1002/ijc.31034
pubmed: 28884470
Leonardi MC, Scognamiglio IR, Maisonneuve P et al (2021) Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated. Breast Cancer Res Treat 188(2):511–524. https://doi.org/10.1007/s10549-021-06227-2
doi: 10.1007/s10549-021-06227-2
pubmed: 33905020
Markkula A, Bromée A, Henningson M et al (2012) Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. Cancer Causes Control 23(8):1307–1316. https://doi.org/10.1007/s10552-012-0008-9
doi: 10.1007/s10552-012-0008-9
pubmed: 22695757
Margenthaler JA, Dietz JR, Chatterjee A (2021) The landmark series: breast conservation trials (including oncoplastic breast surgery). Ann Surg Oncol 28(4):2120–2127. https://doi.org/10.1245/s10434-020-09534-y
doi: 10.1245/s10434-020-09534-y
pubmed: 33521897
Mahmood U, Hanlon AL, Koshy M et al (2013) Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol 20(5):1436–1443. https://doi.org/10.1245/s10434-012-2732-5
doi: 10.1245/s10434-012-2732-5
pubmed: 23135312
van Maaren MC, de Munck L, Jobsen JJ et al (2016a) Breast-conserving therapy versus mastectomy in T1–2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients. Breast Cancer Res Treat 160(3):511–521. https://doi.org/10.1007/s10549-016-4012-8
doi: 10.1007/s10549-016-4012-8
pubmed: 27730424
van Maaren MC, de Munck L, de Bock GH et al (2016b) 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol 17(8):1158–1170. https://doi.org/10.1016/S1470-2045(16)30067-5
doi: 10.1016/S1470-2045(16)30067-5
pubmed: 27344114
(1991) NIH Consensus Development Conference statement on the treatment of early-stage breast cancer. Oncology (Williston Park, NY). 5(2): 120–124.
Sanpaolo P, Barbieri V, Genovesi D (2011) Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 37(10):876–882. https://doi.org/10.1016/j.ejso.2011.07.001
doi: 10.1016/j.ejso.2011.07.001
pubmed: 21824742
Thorat MA, Levey PM, Jones JL et al (2021) Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: results from the UK/ANZ DCIS randomized trial. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-1239
doi: 10.1158/1078-0432.CCR-21-1239
pubmed: 34380636
pmcid: 7612534
Torres-Roca JF, Fulp WJ, Caudell JJ et al (2015) Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer. Int J Radiat Oncol Biol Phys 93(3):631–638. https://doi.org/10.1016/j.ijrobp.2015.06.021
doi: 10.1016/j.ijrobp.2015.06.021
pubmed: 26461005
pmcid: 5811194
Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232. https://doi.org/10.1056/NEJMoa020989
doi: 10.1056/NEJMoa020989
pubmed: 12393819
Veronesi U, Saccozzi R, Del Vecchio M et al (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 305(1):6–11. https://doi.org/10.1056/NEJM198107023050102
doi: 10.1056/NEJM198107023050102
pubmed: 7015141
Vila J, Gandini S, Gentilini O (2015) Overall survival according to type of surgery in young (≤40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast 24(3):175–181. https://doi.org/10.1016/j.breast.2015.02.002
doi: 10.1016/j.breast.2015.02.002
pubmed: 25728282
Wang J, Wang S, Tang Y et al (2018) Comparison of treatment outcomes with breast-conserving surgery plus radiotherapy versus mastectomy for patients with stage I breast cancer: a propensity score-matched analysis. Clin Breast Cancer 18(5):e975–e984. https://doi.org/10.1016/j.clbc.2018.06.002
doi: 10.1016/j.clbc.2018.06.002
pubmed: 30054238
Wrubel E, Natwick R, Wright GP (2021) Breast-conserving therapy is associated with improved survival compared with mastectomy for early-stage breast cancer: a propensity score matched comparison using the National Cancer Database. Ann Surg Oncol 28(2):914–919. https://doi.org/10.1245/s10434-020-08829-4
doi: 10.1245/s10434-020-08829-4
pubmed: 32661849